Cempra Details Launch Plans For Solithromycin
Expecting approval for CABP before the end of 2016, Cempra says solithromycin will offer a significant treatment-resistance edge over the earlier macrolide antibiotic azithromycin.
Expecting approval for CABP before the end of 2016, Cempra says solithromycin will offer a significant treatment-resistance edge over the earlier macrolide antibiotic azithromycin.